title: Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma.
authors.affiliation: University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, 1720 2nd Avenue South, Birmingham, Alabama 35294, USA.
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.affiliation: Dana Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.
authors.forename: Joaquim
authors.initials: J
authors.lastname: Bellmunt
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000077143:Docetaxel; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D043823:Taxoids / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D019459:Urothelium / Q000187:drug effects* / Q000473:pathology; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077143:Docetaxel; D043823:Taxoids; D000096662:Ramucirumab